Covance Enhances Custom Antibody Production Capabilities With State-Of-The-Art Antibody Purification System
|View printer-friendly version||<< Back|
— New automated system produces highest quality results for custom immunology services —
Princeton, NJ, April 9, 2007 — today announced the addition of a state-of-the-art antibody purification system for monoclonal and polyclonal antibodies, offering customers the highest quality antibody production through greater efficiency, reliability, and reproducibility for antibody purification.
The automated, high-performance liquid chromatography equipment will be used for the purification of monoclonal and polyclonal antibodies from serum, ascites, and cell culture supernatant. The system has the flexibility to perform a wide variety of other chromatographic techniques such as antigen-specific affinity purifications and size exclusion chromatography.
The combination of highly sensitive computer-controlled pumps and UV conductance meters, along with automatic scouting runs which systematically vary different parameters, allows for more reproducible results. Controlled by a software platform designed specifically for the evaluation and reporting of laboratory data, the system enables greater reliability of results through software which provides GLP compliance via audit trails, verification of deviations, and data reporting.
As one of the research market's largest providers of custom antibodies, Covance can ensure the highest quality and attention to detail for its custom antibody work. Covance offers a full range of custom immunology services including monoclonal and polyclonal antibody production, hybridoma development, vaccine testing and immunochemistry, and antibody products and detection reagents.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and more than 8,100 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance are registered service marks of Covance in the United States and other countries.